[1]丁贤彬,吕晓燕,毛德强.2006至2014年重庆市宫颈癌发病趋势分析[J].重庆医科大学学报,2016,41(3):282-285. [2]李奕彤,王雅棣,张富利,等.宫颈癌调强放疗中靶区变化与剂量分析[J].中华放射医学与防护杂志,2015,35(10):751-755. [3]Chen CC,Wang L,Lin JC,et al.The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy[J].J Formos Med Assoc,2015,114(3):231-237. [4]周晖,卢淮武,彭永排,等.《2015年NCCN宫颈癌临床实践指南》解读[J].中国实用妇科与产科杂志,2015,31(3):185-191. [5]Trotti A,Colevas A D,Setser A,et al.CTCAE v3.0:development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-178. [6]Aaronson NK,Ahmedzai S,Bergman B,et al.The European Organization for Research and Treatment of Cancer QLQ-C30:a quality-of-life instrument for use in international clinical trials in oncology [J].J Natl Cancer Inst,2005,85(5):365-376. [7]Wright TC,Stoler MH,Behrens CM,et al.Primary cervical cancer screening with human papillomavirus:end of study results from the ATHENA study using HPV as the first-line screening test[J].Gynecol Oncol,2015,136(2):189-197. [8]刘慧强.我国宫颈癌流行病学特征和高危因素分析[J].中国妇幼保健,2016,31(6):1258-1260. [9]李兴兰,盛修贵.子宫颈癌调强放疗的研究进展[J].中华妇产科杂志,2014,49(9):710-712. [10]李龄,高颖川,朱小东,等.鼻咽癌调强放疗疗效及局部复发的剂量学因素分析[J].肿瘤防治研究,2014,41(4):353-357. [11]葛倩,王邈,李晨龙,等.p53与胃肠道恶性肿瘤相关性的研究进展[J].中国中西医结合消化杂志,2016,24(4):317-320. [12]张仁峰,公蕾.p53基因与肿瘤治疗研究进展[J].现代免疫学,2016,36(2):150-153. [13]Zarogoulidis P,Hohenforst-Schmidt W,Darwiche K,et al.Gene therapy with DDMC-p53 with or without cisplatin and microwave ablation.A future concept for local treatment in lung cancer[J].Eur Respir J,2015,46(suppl 59):PA4291- PA4293. [14]Sheng S,Zheng J,Cui S,et al.Complete remission of multiple lung metastases after ablation of hepatocellular carcinoma by transarterial infusion with the p53 gene [J].Anticancer Drugs,2015,26(2):227-231.
2017, Vol. 34 
